YIH
TBPH icon

Y-Intercept (HK)’s Theravance Biopharma TBPH Stock Holding History

Y-Intercept (HK)’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,686
Closed -$350K – 2040
2025
Q4 		$350K Buy
+18,686
New +$310K 0.01% 1335
2025
Q3 		– Sell
-40,943
Closed -$452K – 2036
2025
Q2 		$452K Buy
+40,943
New +$398K 0.01% 1239
2024
Q4 		– Sell
-31,194
Closed -$251K – 1643
2024
Q3 		$251K Buy
+31,194
New +$270K 0.02% 1078
2023
Q4 		– Sell
-16,137
Closed -$139K – 1632
2023
Q3 		$139K Buy
+16,137
New +$156K 0.01% 941

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s TBPH Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 18,686 shares — an estimated $350K sold.

Y-Intercept (HK) first reported a position in TBPH in Q3 2023 and held it in 4 quarters. The position peaked at $452K in Q2 2025. 174 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Y-Intercept (HK) reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 18,686 Theravance Biopharma shares in Q1 2026, an estimated $350K.
  • Y-Intercept (HK) first reported a position in Theravance Biopharma in Q3 2023 and held it in 4 quarters.
  • Y-Intercept (HK)'s Theravance Biopharma position peaked at $452K in Q2 2025.
  • 174 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.